Neil Steven

Neil Steven

Auto-generated profile, based on publicly available information

Neil Steven

University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
SCStelios Chrysostomou
Stelios Chrysostomou
RRRajat Roy
Rajat Roy
FPFilippo Prischi
Filippo Prischi
LTLucksamon Thamlikitkul
Lucksamon Thamlikitkul
KCKathryn L. Chapman
Kathryn L. Chapman
Olivier E. PardoOlivier E. Pardo
Olivier E. Pardo
Lung and bladder cancers are mostly incurable because of the early development of drug resistance and metastatic dissemination. Hence, improved therapies that tackle these two processes are urgently needed to improve clinical outcome. We have identified RSK4 as a promoter of drug resistance and metastasis in lung and bladder cancer cells. Silencing this kinase, through either RNA interference or CRISPR, sensitized tumor cells to chemotherapy and hindered metastasis in vitro and in vivo in a tail vein injection model. Drug screening revealed several floxacin antibiotics as potent RSK4 activation inhibitors, and trovafloxacin reproduced all effects of RSK4 silencing in vitro and in/ex vivo using lung cancer xenograft and genetically engineered mouse models and bladder tumor explants. Through x-ray structure determination and Markov transient and Deuterium exchange analyses, we identified the allosteric binding site and revealed how this compound blocks RSK4 kinase activation through binding to an allosteric site and mimicking a kinase autoinhibitory mechanism involving the RSK4’s hydrophobic motif. Last, we show that patients undergoing chemotherapy and adhering to prophylactic levofloxacin in the large placebo-controlled randomized phase 3 SIGNIFICANT trial had significantly increased (P = 0.048) long-term overall survival times. Hence, we suggest that RSK4 inhibition may represent an effective therapeutic strategy for treating lung and bladder cancer.

20 March 2025 in Journal of Clinical Oncology
Verified
Journal Article
Open access
SBShailender Bhatia
Shailender Bhatia
STSuzanne L. Topalian
Suzanne L. Topalian
WSWilliam Sharfman
William Sharfman
TMTim Meyer
Tim Meyer
NSNeil Steven
Neil Steven
PNPeter P. Nghiem
Peter P. Nghiem
PURPOSE: Approximately 50% of patients with advanced Merkel cell carcinoma (MCC) have primary or acquired resistance to PD-(L)1 blockade, which may be overcome using combination immune checkpoint inhibition (ICI) with anti–cytotoxic T lymphocyte antigen-4 antibody. We present results from the recurrent/metastatic MCC cohort in CheckMate 358, a nonrandomized, multicohort, phase I/II study of nivolumab (NIVO) with or without ipilimumab (IPI) in virus-associated cancers (ClinicalTrials.gov identifier: NCT02488759 ). METHODS: ICI-naïve patients with recurrent/metastatic MCC and 0-2 previous systemic therapies were administered NIVO monotherapy at 240 mg once every 2 weeks or combination therapy with NIVO 3 mg/kg once every 2 weeks + IPI 1 mg/kg once every 6 weeks. The primary end point was objective response. Secondary end points included duration of response (DOR), progression-free survival (PFS), and overall survival (OS). RESULTS: Sixty-eight patients received NIVO (n = 25) or NIVO + IPI (n = 43). The objective response rate (95% CI) and median DOR (95% CI), respectively, were 60% (38.7 to 78.9) and 60.6 months (16.7 to not applicable [NA]) with NIVO and 58% (42.1 to 73) and 25.9 months (10.4 to NA) with NIVO + IPI. The median PFS (95% CI) and OS (95% CI), respectively, were 21.3 (9.2 to 62.5) and 80.7 (23.3 to NA) months with NIVO and 8.4 (3.7 to 24.3) and 29.8 (8.5 to 48.3) months with NIVO + IPI. The incidence of grade 3/4 treatment-related adverse events was 28% with NIVO and 47% with the combination. CONCLUSION: This nonrandomized study showed frequent and durable responses with both NIVO and NIVO + IPI in patients with ICI-naïve advanced MCC. However, it did not show improvement in efficacy with the combination, thus contradicting previous study reports that had suggested clinical benefit with combination ICI. A randomized trial of NIVO + IPI versus NIVO monotherapy is warranted.

1 December 2025 in Efficacy and Mechanism Evaluation
Verified
Journal Article
Open access
NSNeil M Steven
Neil M Steven
SPSarah Pirrie
Sarah Pirrie
YJYolande Jefferson-Hulme
Yolande Jefferson-Hulme
CGClaire H Gaunt
Claire H Gaunt
VHVictoria Homer
Victoria Homer
Background: Merkel cell carcinoma is a rare locally invasive skin cancer of older people. Standard management for primary Merkel cell carcinoma is surgery and/or radiotherapy, with no standard of care or unity of practice, based on retrospective experience without randomised trials. Objectives: Feasibility objectives were to determine whether Rational Compare was likely to deliver on its objectives to influence individual treatment decisions and clinical practice, and to determine operational adaptations to reduce variation between patients and in non-randomised components of the management pathway. If the feasibility objectives were met, then the primary objective of the overall trial was to determine if surgery or radiotherapy as first definitive treatment for primary Merkel cell carcinoma results in better loco-regional disease control. Design: Rational Merkel cell carcinoma was a multicentre, two-arm, randomised Phase III, adaptive trial with integrated feasibility phase (Rational Compare) plus observational study (Rational Review) designed to produce probabilities that wide local excision or radiotherapy as first treatment for primary Merkel cell carcinoma was at least as good or better than the other in terms of loco-regional control. In the observational protocol (Rational Review), definitive treatment was allocated by regional Specialist Skin Cancer Multidisciplinary Teams to maximise data on this rare cancer. Setting: National Health Service hospitals with Specialist Skin Cancer Multidisciplinary Teams. Participants: All patients with newly presenting histologically proven Merkel cell carcinoma considered for radical loco-regional control without distant metastases, capable to consent, were eligible for the trial. Randomisation occurred using a bespoke computer randomisation system developed by the Cancer Research UK Clinical Trials Unit employing a stratified minimisation method. Those with primary Merkel cell carcinoma that could be treated with margins of ≥ 1 cm by either surgery or radiotherapy for which the Specialist Skin Cancer Multidisciplinary Team was in equipoise were eligible for Rational Compare. Interventions: Wide local excision or radiotherapy as first definitive treatment for primary Merkel cell carcinoma. Main outcome measures: Time from randomisation to loco-regional treatment failure. Rates of registration and randomisation. Marginal excision and macroscopic disease at the time of definitive treatment. Results: Sixty-four patients were recruited, of whom five were randomised. The trial did not meet its feasibility target for randomisation and closed. The five randomised patients all underwent their allocated treatment (three radiotherapy and two surgery, one with adjuvant radiotherapy following surgery), and none experienced loco-regional failure. Twenty-six loco-regional failure events were reported in 59 observational patients (8 had radiotherapy, 27 had surgery, 18 had surgery with adjuvant radiotherapy, 5 had regional Merkel cell carcinoma without known primary and 1 unknown treatment). About a quarter of patients had macroscopic disease, and a majority likely had microscopic involvement at the primary site at the time of definitive treatment. Conclusions: Both wide local excision and radiotherapy are offered as first treatment for primary Merkel cell carcinoma in UK practice, but it remains uncertain whether one should be prioritised. Implications for health care: As Merkel cell carcinoma is a rare cancer, the challenge for healthcare systems has been that no specific management strategy currently exists. Merkel cell carcinoma requires a more definitive guideline with optimised referral pathways and interhospital working, which could accelerate and clarify treatments and thus allow better comparison and improvement of outcomes. Limitations: Major logistic challenges meant randomisation targets were not met, so the trial closed without answering the primary objective. Future work: The design and outcomes of Rational Merkel cell carcinoma will inform design of future studies for rare cancers. Readouts of circulating immune cells and analysis of the immune microenvironment in the Merkel cell carcinoma primary will be explored in relation to the clinical data set and outcomes. Study registration: This study is registered as ISRCTN16290169; Clinicaltrials.gov number NCT05253144. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Efficacy and Mechanism Evaluation programme (NIHR award ref: 12/205/36) and is published in full in Efficacy and Mechanism Evaluation ; Vol. 12, No. 12. See the NIHR Funding and Awards website for further award information.

20 May 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SESarah Gabrielle Ellis
Sarah Gabrielle Ellis
LPLalit Pallan
Lalit Pallan
MHMirela Hategan
Mirela Hategan
NPNicola Price
Nicola Price
HAHendrik-Tobias Arkenau
Hendrik-Tobias Arkenau
MWMatthew James Wheater
Matthew James Wheater
E21027Background: Combination BRAF and MEK inhibition in mm has demonstrated improved Overall Survival (OS) and Progression Free Survival (PFS) compared to single agent BRAF inhibition (BRAFi) in phase III testing. Access to the combination in the UK was through a named patient programme for patients with unresectable stage III or IV BRAF mutant melanoma from July 2013. We report on outcome and toxicity data for the cohort. Methods: Retrospective data was collected from casenote and database review of patients treated in 5 UK centers. Physician assessment of response and toxicity was recorded. PFS and OS were calculated from the date of start of treatment to progressive disease or death. Patients still alive or progression free were censored at last clinical review. Results: 73 patients were treated with a median age 55, (range 20 -77). 31 were treatment naïve, 13 had prior immunotherapy. A large proportion (49.3%) received prior BRAFi with Vemurafenib. 20.5% of patients had brain metastases at initiation...

14 November 2019 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Closed access
PDF file
SBSmriti Bose
Smriti Bose
SSSalini Sumangala
Salini Sumangala
NSNeil Steven
Neil Steven
SJSaiju Jacob
Saiju Jacob
Objective The use of immune checkpoint inhibitors (CIs) for malignancies has revolutionised oncological management in the last few years. These agents are known to cause immune-mediated complications in various systemic organs. The neurological complications of these are now being increasingly recognised. The cases managed in our institution where there were neuroimmunological complications following CIs were reviewed. We discuss management strategies for early recognition and treatment, thus minimising morbidity. Method A joint effort by neurologists and medical oncologists to review clinical practice guidelines for management of neurological adverse effects of checkpoint inhibitors. This was based on a review of several cases reported, as well as experience from all the cases managed in our hospital. Results There are no British guidelines from the neurological perspective for early identification of symptoms. Guidelines are based on expert consensus and also on treatments reviewed from literature. Conclusion Recommendations advice early identification of signs and symptoms followed by grading them as mild, moderate and severe (grades 1, 2, 3). Grade 1 symptoms require continuation of the CIs and symptomatic management. CIs should be stopped temporarily for grade 2 and permanently for grade 3 symptoms. Steroids plasma exchange, IVIg would be the first line of treatment.